According to the STAR*D research trial on treating depression, which therapy would be considered the most appropriate first line drug to use?

The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial was a large, study evaluating stepwise treatment strategies for major depressive disorder when initial therapies fail or require adjustment. It helped establish evidence-based sequencing of antidepressant therapies and confirmed that selective serotonin reuptake inhibitors (SSRIs) are appropriate first-line agents due to their efficacy and tolerability profile. Treatment selection prioritizes safety, side effect burden, and patient adherence in long-term depression management. Rationale: A. Buspirone (Buspar) is primarily indicated for generalized anxiety disorder and is not considered a first-line antidepressant for major depressive disorder. While it can be used as an adjunct to antidepressants, it lacks strong antidepressant efficacy as monotherapy. Therefore, it is not appropriate as initial treatment for depression in the STAR*D framework. B. Alprazolam (Xanax) is a benzodiazepine used for acute anxiety and panic symptoms, not for long-term management of depression. It does not treat the underlying pathophysiology of major depressive disorder and carries risks of dependence, tolerance, and sedation. It is not recommended as a first-line or standalone treatment for depression. C. Amitriptyline (Elavil) is an older antidepressant effective for depression but associated with significant side effects such as anticholinergic effects, orthostatic hypotension, and cardiotoxicity in overdose. Due to its safety profile, it is not considered first-line therapy in modern treatment algorithms, including STAR*D, which favors safer SSRIs initially. D. Escitalopram (Lexapro) is a selective serotonin reuptake inhibitor and is considered first-line therapy for major depressive disorder in the STAR*D trial and current clinical guidelines. It has strong efficacy, a favorable side effect profile, and good tolerability compared to older antidepressants. These characteristics make it an appropriate initial pharmacologic choice for depression treatment.